SVF
Level D· Preclinical EvidenceAnimal Study

Tumor necrosis factor-α-stimulated gene 6 promotes hematoma clearance after intracerebral hemorrhage in a mouse model.

Liu X., Yao D., Li Y., Chen S., Tang Y., Wang J.

Animal Study on Chronic Inflammation, published in Neural Regen Res (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Neural Regen Res (2026)
Country
India
Reported sample size
—
PMID
40537016
DOI
10.4103/NRR.NRR-D-24-00968

Abstract (original English)

The prognosis for patients who experience intracerebral hemorrhage is poor because of a lack of effective treatments. Tumor necrosis factor-α–stimulated gene 6 (TSG6) is a secreted glycoprotein that exerts anti-inflammatory effects in various inflammatory diseases. We previously showed that adipose-derived stem cells can inhibit inflammation by upregulating TSG6 secretion in an in vitro model of intracerebral hemorrhage. However, the direct effects of TSG6 on hematoma clearance in vivo remain largely unknown. The aim of this study was to determine how TSG6 affects hematoma absorption in mice subjected to intracerebral hemorrhage and to explore the potential underlying mechanisms. We first analyzed the gene profiles of patients with intracerebral hemorrhage from the GEO database and examined changes in TSG6 expression in the brain tissues of mice subjected to intracerebral hemorrhage. We found that TSG6 expression exhibited a transient increase following intracerebral hemorrhage, and that there was a negative correlation between the initial hematoma volume and TSG6 levels. Immunofluorescence analysis showed that TSG6 was primarily expressed in microglia and macrophages. Furthermore, we found that TSG6 promoted functional recovery in mice subjected to intracerebral hemorrhage by accelerating hematoma clearance, reducing the number of apoptotic cells and degenerated neurons, incre

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Face & SkinChronic Inflammation
View on PubMedDOI

Related research